Dr. James F. Dylewski, D.O.
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 62
Licensed in Colorado since 2017, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
CO license DR.0059575 (first issued 2017; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Denver Health & Hospital Authority Denver, CO
Medical groups
- Denver Health and Hospital Authority (849 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 62
- Services billed
- 227
- Patients’ average age
- 65
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 48 | 25 |
| Hemodialysis procedure with physician evaluation | 35 | 14 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 28 | 13 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Jardiance (empagliflozin) Other prescribers in Denver, CO | 18 |
| Amlodipine Besylate Other prescribers in Denver, CO | 15 |
| Spironolactone Other prescribers in Denver, CO | 15 |
| Furosemide Other prescribers in Denver, CO | 14 |
| Losartan Potassium Other prescribers in Denver, CO | 14 |
| Jynarque (tolvaptan) | 13 |
| Velphoro (sucroferric oxyhydroxide) | 11 |
| Samsca (tolvaptan) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $3,062 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND Study)
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.